Immunotherapy, a revolutionary approach in the fight against cancer, has been rapidly evolving over the past decade. Harnessing the power of the body's immune system, it presents a promising alternative to traditional treatments, offering new hope to patients worldwide.
Immunotherapy, also known as biologic therapy, involves the use of substances to stimulate or suppress the immune system, aiding it in detecting and combating cancer cells. It can be categorized into several types, including immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer.
These inhibitors work by blocking immune checkpoints, proteins used by cancer cells to evade the immune system. By inhibiting these checkpoints, the immune system can better recognize and attack cancer cells. Notable drugs in this category include Pembrolizumab and Nivolumab.
Cancer vaccines, much like traditional vaccines, aim to trigger an immune response. However, instead of preventing disease, these vaccines treat existing cancer by instructing the immune system to attack specific cancer cells.
Adoptive cell transfer involves the modification of a patient's T cells to enhance their ability to fight cancer. CAR-T cell therapy, a type of adoptive cell transfer, has shown remarkable success in treating certain types of lymphomas and leukemias.
Despite its potential, immunotherapy faces several challenges, including unpredictable responses and severe side effects. However, ongoing research and advancements in precision medicine aim to overcome these obstacles, paving the way for more effective and personalized treatments.
Immunotherapy represents a significant paradigm shift in oncology, offering a novel and potent weapon in the battle against cancer. As physicians, it is crucial to stay abreast of these developments, integrating them into practice to provide the best possible care for our patients.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation